J
Jan-Arne Björkman
Researcher at AstraZeneca
Publications - 27
Citations - 752
Jan-Arne Björkman is an academic researcher from AstraZeneca. The author has contributed to research in topics: Metoprolol & Hemodynamics. The author has an hindex of 15, co-authored 27 publications receiving 718 citations.
Papers
More filters
Journal ArticleDOI
Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model:
TL;DR: Ticagrelor inhibits adenosine uptake in vitro and subsequently augments cardiac blood flow in a canine model of reactive hypoxia- or adenosin-induced blood flow increases, suggesting that ticag Relor may have additional benefits in patients with acute coronary syndrome beyond inhibition of platelet aggregation.
Journal ArticleDOI
Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis
TL;DR: It is suggested that reversibility of P2Y(12) binding with ticagrelor may account for the greater separation between antithrombotic effects and increased bleeding compared with the irreversible binding of clopidogrel and prasugrel.
Journal ArticleDOI
The role of sympathetic activity in atherogenesis: Effects of β-blockade
Bengt Åblad,Jan-Arne Björkman,David Gustafsson,Göran K. Hansson,Ann-Margret Östlund-Lindqvist,Knut Pettersson +5 more
TL;DR: Clinical and experimental evidence points to potential antiatherosclerotic effects of certain β-adrenoreceptor antagonists, and it is suggested that a retardation of atherosclerosis development might have contributed to the reduced incidence of cardiovascular complications.
Journal ArticleDOI
Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone
Journal ArticleDOI
Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
Peter Bach,Thomas Antonsson,Ruth Bylund,Jan-Arne Björkman,Krister Österlund,Fabrizio Giordanetto,J.J.J. van Giezen,Søren M. Andersen,Helen Zachrisson,Fredrik Zetterberg +9 more
TL;DR: In a modified Folts model in dog, both piperidine 3 and azetidine 13 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, respectively.